What the Study Found (In Plain English)
Published in Human vaccines & immunotherapeutics (2024), this phase iii randomized trial evaluating human clinical outcomes investigated: This open-label, randomized, phase 3 study in China (V260-074; NCT04481191) evaluated the immunogenicity and safety of concomitant and staggered administration of three doses of an oral, live, pentavalent rotavirus vaccine (RV5) and three doses of an intramuscular, inactivated poliomyelitis vaccine (IPV) in 400 healthy infants. Key clinical takeaway: No safety concerns were identified. These data support the concomitant use of RV5 and IPV in healthy Chinese infants.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Human vaccines & immunotherapeutics, 2024-12-31; Phase III Randomized Trial; Rigor 82/100): No safety concerns were identified. These data support the concomitant use of RV5 and IPV in healthy Chinese infants.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.